No, But i will dump on the bid if I have to. All shares are free with 20k profit so anything is extra. Just cleaning up my accounts to get dead money out Win, Lose, or Draw. I have recently learned how to trade options and it is working very well for me. GL all

Got my sell order in too many other opportunities, so once my order fills then she can move up.LOL

Open Sell 120000
ENMI

Limit
0.035
--
06
22
22
--


Dh Enchantment Inc Common... Bid: 0.015

Ask: 0.027

Last: 0.021

Tax Lot ID Method:Your standing method

Entered:12:35:17 03/29/22 Reuse

Just let this bust through this 2.00-2.05 level

Oh I am patient I am here from May 2020 with average cost .14

Good god let this thing friggin run

Should rocket tommorow

MariMed Doubles Full Year Revenue and Adjusted EBITDA As It Reports Fourth Quarter and Full Year 2021 Earnings
4:00 pm ET March 16, 2022 (Globe Newswire) Print
MariMed, Inc. (OTCQX: MRMD) ("MariMed" or the "Company"), a leading multi-state cannabis operator focused on improving lives every day, today announced its financial and operating results for the fourth quarter and full year ended December 31, 2021.

FOURTH QUARTER AND FULL YEAR FINANCIAL HIGHLIGHTS

"We are very pleased to deliver another strong year of financial performance for our shareholders, more than doubling our revenue and Adjusted EBITDA," said Bob Fireman, President and Chief Executive Officer of MariMed. "Our validated management team continued to grind it out, staying focused on the financial discipline and operational excellence that has defined our approach. We strengthened an already solid balance sheet through our operating cash flow generation and made great progress across all four pillars of our strategic growth plan."

* Adjusted EBITDA is a non-GAAP measure explained in the section below entitled Non-GAAP Financial Measure, which includes a table showing the adjustments to the Company's net income that results in Adjusted EBITDA.

FOURTH QUARTER AND FULL YEAR OPERATIONAL HIGHLIGHTS

The continued strong financial performance in the fourth quarter of 2021 was driven by:

SUBSEQUENT EVENTS

Subsequent to the end of the 2021 fiscal year, the Company announced several significant business developments, including:

STRATEGIC GROWTH PLAN

Going forward, the Company expects continued strong financial performance through the execution of the four key components of its strategic growth plan: (1) Completing the consolidation of the Company's state cannabis licensed operations it developed and currently manages; (2) Increasing revenues in current cannabis state businesses, by spending capital to increase the capacity at its cultivation and production facilities as well as adding more retail stores; (3) Expanding the Company's footprint into additional legal cannabis states through new license applications and M&A; and (4) Expanding the manufacturing and distribution of its portfolio of leading brands into additional states by licensing to qualified partners or acquiring production and distribution cannabis businesses.

2022 FINANCIAL TARGETS

Considering MariMed's strategic plan to drive long-term growth, recent acquisitions, license wins, and current industry dynamics, the Company has set the following financial targets for the full fiscal year 2022:

"After setting financial targets in 2021 for the first time, and subsequently raising and beating them, I am pleased to announce very strong financial growth targets for 2022," said Jon Levine, Chief Financial Officer of MariMed. "Our strict financial discipline combined with our outstanding operations give us confidence we will meet or beat our full year financial guidance once again in 2022."

CONFERENCE CALL

MariMed management will host a conference call on Thursday, March 17, 2022, to discuss these results at 8:00 a.m. Eastern time. The conference call may be accessed through MariMed's Investor Relations website by clicking the following link: MariMed Q421 Earnings Call.

Earnings Release Tables
Financial Summary: Q421 vs Q420
($US thousands) Q4 2021 Q4 2020 Y/Y Change (%)
(Unaudited)
Revenues $ 31,044 $ 20,357 52%
Gross Profit $ 15,490 $ 11,619 33%
Operating Expenses $ 14,286 $ 3,580 299%
Adj. EBITDA $ 8,262 $ 8,840 -7%
Adj. EBITDA Margin 26.6% 43.4%
Cash Provided By Operations $ 7,930 $ 1,774 347%
Working Capital $ 17,390 $ (2,183) -
NON-GAAP FINANCIAL MEASURE

The Company has provided in this release the non-GAAP financial measure of Adjusted EBITDA as a supplement to Revenues, Gross Profit, and other financial measures prepared in accordance with GAAP.

Management defines Adjusted EBITDA as net income, determined in accordance with GAAP, excluding the following:

Management believes Adjusted EBITDA is a useful measure to assess the performance and liquidity of the Company as it provides meaningful operating results by excluding the effects of expenses that are not reflective of its operating business performance. In addition, the Company's management uses Adjusted EBITDA to understand and compare operating results across accounting periods, and for financial and operational decision making. The presentation of Adjusted EBITDA is not intended to be considered in isolation or as a substitute for the financial information prepared in accordance with GAAP.

Management believes that investors and analysts benefit from considering Adjusted EBITDA in assessing the Company's financial results and its ongoing business as it allows for meaningful comparisons and analysis of trends in the business. Adjusted EBITDA is used by many investors and analysts themselves, along with other metrics, to compare financial results across accounting periods and to those of peer companies.

As there are no standardized methods of calculating non-GAAP measurements, the Company's calculations may differ from those used by analysts, investors, and other companies, even those within the cannabis industry, and therefore may not be directly comparable to similarly titled measures used by others.

The table below reconciles Net Income (Loss) to Adjusted EBITDA for the three months and full years ended December 31, 2021 and 2020:

EBITDA & ADJUSTED EBITDA RECONCILIATION
Three Months Ended Twelve Months Ended
December 31, December 31,
($US thousands) 2021 2020 2021 2020
(Unaudited)
Net income (loss) $ (6,398) $ 4,212 $ 7,624 $ 2,429
Interest expense, net $ 267 $ 2,194 $ 2,248 $ 9,654
Income taxes $ 7,166 $ 2,067 $ 16,192 $ 2,067
Depreciation and amortization $ 771 $ 534 $ 2,788 $ 2,182
Earnings Before Interest, Taxes and Depreciation & Amortization $ 1,805 $ 9,007 $ 28,852 $ 16,333
Amortization of stock grants $ 2 $ 5 $ 235 $ 21
Amortization of option grants $ 6,286 $ 262 $ 12,494 $ 969
Amortization of stand-alone warrant issuances $ - $ - $ 56 $ 2
Legal settlement $ - $ - $ (267) $ -
Amortization of warrants issued with stock $ - $ - $ 655 $ -
Loss on equity issued to settle obligations $ - $ (80) $ 3 $ 45
Write-down of intangible assets $ - $ - $ - $ 85
Equity in earnings of investments $ - $ - $ - $ (99)
Change in fair value of investments $ 169 $ (355) $ 1,107 $ 350
Adjusted EBITDA $ 8,262 $ 8,840 $ 43,134 $ 17,706

Not me still waiting for .75 LOLLLLL. With this rise in covid cases and shortage on tests they should be selling them like crazy. Maybe we pool some money and place a big order and then resell. LOL

My apologies I didnt read the post you were responding to.

I dont think that is a comparison. Because IIPR doesnt sell canabis but is a REIT. I dont think they would be looking to buy MRMD. They basically are the bank.


Innovative Industrial Properties (NYSE:IIPR) is a pot stock, but it doesn't sell any legal cannabis itself. Instead, this real estate investment trust (REIT) provides the medical marijuana industry with operating facilities and scarce capital.Dec 2, 2021

And of course If you think about it from this next couple of TRADES WE SHOULD HIT A 5X!!!

I have no intentions of selling anytime soon as I lookback my first buy was 05/2020 and accumilated more through 11/2020 and sold some in 8/20 and 11/20 which gives nme a .1364 price so I have alot of padding. With this consolidation .60-1.20 since Jan 2021 when we breakout it will run hard with 2.00 then 2.75-2.85 and then 3.30+. All IMO

Just hate how this stock trades, such manipulation nice moves up just to get smacked down hard. LOL Dont plan on selling my .16s anytime soon so most days I just ignore it

I have been following this stock for a couple months and started buying the last 2 weeks. averaging about .027. I like the share structure and the fact that management is constantly communicating to shareholders.

This is why. I think
Part II - Rules 12b-25(b) and (c)



If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed.(Check box if appropriate.)

v (a) The reason described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense.
(b) The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-SAR or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and
(c) The accountant's statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.


Part III – Narrative



State below in reasonable detail why Forms 10-K, 20-F, 11-K, 10-Q,10-D, N-SAR, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period.



The Registrant is unable to file its Quarterly Report on Form 10-Q for the period ended September 30, 2021 (the "10-Q") within the prescribed time period without unreasonable effort or expense due to the additional administrative burdens associated with the recent acquisition of its operating company. The Registrant will file the 10-Q on or before the fifteenth calendar day following the prescribed due date.



Part IV - Other Information



1. Name and telephone number of person to contact in regard to this notification

Yup but they also updated profile, so hopefully its temporary

WTF back to Expert market

Very nice. Patience here will pay us. GL

I would not be a shorter dont see were its over extended and could rally atany point. I am very patient and plan to hold this for a long time as I stated previous my cost is .16 and i see 2.00 quickly once we break back over 1.20. IMO

I am not looking to add as my cost is .16 and am not going nowhere, just would like to see this get back over $1 for good especially with a company turning a profit and cash in the bank.GL

i dont KNow where you read that but this came from the co website. The Company is maintaining full year 2021 financial guidance of $118 million in revenue and $42 million in Adjusted EBITDA.

I might adjust if rises quickly. I have nothing invested here as I took all investment out plus a nice profit. These guys bought this company with a plan and I dont think going Expert was part of it. We are going up on hundreds of shares. Bring a multy million share day and easy 1.00 IMO

I know Barbara is no longer involved here, but she still is in AM*M which is banging hard. Just wasnt able to buy enough shares

I have sell order @1.00 120,000

Ya just pissed we couldnt have bought sub .02, would have liked to loaded .005s best today maybe .05

With the reduced share count this can hop skip and jump to .25-.30

I am glad they corrected and refiled the form and brought us back to pink because it shows they are working in the right direction and not just letting the thing stay black. If everthing had been correct in Sept we would have stayed in the .10-.15 range. IMO

I think there is a bigger picture plan here, my understanding of the drop in listing was some of the info was not complete. That form 10 was submitted in Sept and resubmitted now is almost identical.

WTF moving on up and I cant buy. When we go back to Pink it will open .05++

No I did not see that but it is the same from Sept, but it might have updated info. But tells me they are trying to get things done and now need to wait on OTC to change status.

I think something is going to happen also. I did speak to the new companus lawyer and she said that they were working to get all the fiilings correct and said there intentions were to uplist higher then Barbara had it.Which means OTCQX or something. But I dont know if this is true.I wish I could buy because this aint over. I believe they have a bigger picture plan. All in my opinion

Still wish Barbara stayed involved with the dam Lithium play her other co AM*M banging ready for a 50% move IMO

Still wish Barbara stayed involved with the dam Lithium play her other co AM*M banging ready for a 50% move IMO

Wish I had more cash to load more in the .20s. Only was able to get small position .23

Completly true, but something tells me there is a bigger picture plan here.
Not sure what but all we can do now is wait and see.

We have action today. OH WAIT its down 46% 57,000 shares .0027

Spoke to Fred earlier today. I got confirmation Barbara is no longer involved in ENMI. He was explaining to me that he got real sick in January and had to retire his law practice and they divested from multiple business, that is why Barbara sold out.Also his understanding of why we went from pink back to dark was because it still showed Barbara as an officer and the sec filing didnt match. When we go to OTC now she is no longer listed under officers, contacts, or directors. For what its worth I found Fred very open and was surprised I was able to speak to him.

Barbara should have kept it and merged in Lithium as it said the intentions were. Look at her other lithium play.

I justed dumped another stock with 500.00 profit because of what happened her and I dont want it to happen over there. And that stock isnt even pink only limited. And it looks like it could run good.

I think its self explainetary whats going on. Trust me I am with you its really sucks, because now we will lucky to get out.